|
1
|
Benson RA, McInnes IB, Brewer JM and
Garside P: Cellular imaging in rheumatic disease. Nat Rev
Rheumatol. 11:357–367. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ
and Xu J: Rheumatoid arthritis: Pathological mechanisms and modern
pharmacologic therapies. Bone Res. 6(15)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ma Y, Hong FF and Yang SL: Role of
prostaglandins in rheumatoid arthritis. Clin Exp Rheumatol.
39:162–172. 2021.PubMed/NCBI
|
|
4
|
Dupré DJ, Robitaille M, Rebois RV and
Hébert TE: The role of Gbetagamma subunits in the organization
assembly and function of GPCR signaling complexes. Annu Rev
Pharmacol Toxicol. 49:31–56. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Jia X, Chang Y, Wei F, Dai X, Wu YJ, Sun
XJ, Xu S, Wu HX, Wang C, Yang XZ and Wei W: CP-25 reverses
prostaglandin E4 receptor desensitization-induced fibroblast-like
synoviocyte dysfunction via the G protein-coupled receptor kinase 2
in autoimmune arthritis. Acta Pharmacol Sin. 40:1029–1039.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yang X, Zhao Y, Jia X, Wang C, Wu Y, Zhang
L, Chang Y and Wei W: CP-25 combined with MTX/ LEF ameliorates the
progression of adjuvant-induced arthritis by the inhibition on GRK2
translocation. Biomed Pharmacother. 110:834–843. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Han C, Li Y, Zhang Y, Wang Y, Cui D, Luo
T, Zhang Y, Liu Q, Li H, Wang C, et al: Targeted inhibition of GRK2
kinase domain by CP-25 to reverse fibroblast-like synoviocytes
dysfunction and improve collagen-induced arthritis in rats. Acta
Pharm Sin B. 11:1835–1852. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen J, Wang Y, Wu H, Yan S, Chang Y and
Wei W: A modified compound from paeoniflorin, CP-25, suppressed
immune responses and synovium inflammation in collagen-induced
arthritis mice. Front Pharmacol. 9(563)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tu J, Guo Y, Hong W, Fang Y, Han D, Zhang
P, Wang X, Körner H and Wei W: The regulatory effects of
paeoniflorin and its derivative paeoniflorin-6'-O-benzene sulfonate
CP-25 on inflammation and immune diseases. Front Pharmacol.
10(57)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shu J, Zhang XZ, Han L, Zhang F, Wu Y,
Tang XY, Wang C, Tai Y, Wang QT, Chen JY, et al:
Paeoniflorin-6'-O-benzene sulfonate alleviates collagen-induced
arthritis in mice by downregulating BAFF-TRAF2-NF-κB signaling:
Comparison with biological agents. Acta Pharmacol Sin. 40:801–813.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang BJ, Wang YY, Jia CY, Li SS, Wang XW,
Xu Y, Chen AY, Xu HP, Wang C, Yang ZY, et al:
Paeoniflorin-6'-o-benzene sulfonate ameliorates the progression of
adjuvant-induced arthritis by inhibiting the interaction between
Ahr and GRK2 of fibroblast-like synoviocytes. Int Immunopharmacol.
108(108678)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li J, Xiang B, Su W, Zhang X, Huang Y and
Ma L: Agonist-induced formation of opioid receptor-G
protein-coupled receptor kinase (GRK)-G beta gamma complex on
membrane is required for GRK2 function in vivo. J Biol Chem.
278:30219–30226. 2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rudomanova V and Blaxall BC: Targeting
GPCR-Gβγ-GRK2 signaling as a novel strategy for treating
cardiorenal pathologies. Biochim Biophys Acta Mol Basis Dis.
1863:1883–1892. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang DD, Jiang MY, Wang W, Zhou WJ, Zhang
YW, Yang M, Chen JY and Wei W: Paeoniflorin-6'-O-benzene sulfonate
down-regulates CXCR4-Gβγ-PI3K/AKT mediated migration in
fibroblast-like synoviocytes of rheumatoid arthritis by inhibiting
GRK2 translocation. Biochem Biophys Res Commun. 526:805–812.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chang Y, Jia X, Wei F, Wang C, Sun X, Xu
S, Yang X, Zhao Y, Chen J, Wu H, et al: CP-25, a novel compound,
protects against autoimmune arthritis by modulating immune
mediators of inflammation and bone damage. Sci Rep.
6(26239)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Homan KT and Tesmer JJG: Molecular basis
for small molecule inhibition of G protein-coupled receptor
kinases. ACS Chem Biol. 10:246–256. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Murthy KS, Mahavadi S, Huang J, Zhou H and
Sriwai W: Phosphorylation of GRK2 by PKA augments GRK2-mediated
phosphorylation, internalization, and desensitization of VPAC2
receptors in smooth muscle. Am J Physiol Cell Physiol.
294:C477–C487. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Han CC, Liu Q, Zhang Y, Li YF, Cui DQ, Luo
TT, Zhang YW, Wang XM, Wang C, Ma Y and Wei W: CP-25 inhibits
PGE2-induced angiogenesis by down-regulating
EP4/AC/cAMP/PKA-mediated GRK2 translocation. Clin Sci (Lond).
134:331–347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Penela P, Ribas C and Mayor F Jr:
Mechanisms of regulation of the expression and function of G
protein-coupled receptor kinases. Cell Signal. 15:973–981.
2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jaber M, Koch WJ, Rockman H, Smith B, Bond
RA, Sulik KK, Ross J Jr, Lefkowitz RJ, Caron MG and Giros B:
Essential role of beta-adrenergic receptor kinase 1 in cardiac
development and function. Proc Natl Acad Sci USA. 93:12974–12979.
1996.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tutunea-Fatan E, Abd-Elrahman KS,
Thibodeau JF, Holterman CE, Holleran BJ, Leduc R, Kennedy CRJ, Gros
R and Ferguson SSG: GRK2 knockdown in mice exacerbates kidney
injury and alters renal mechanisms of blood pressure regulation.
Sci Rep. 8(11415)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hullmann J, Traynham CJ, Coleman RC and
Koch WJ: The expanding GRK interactome: Implications in
cardiovascular disease and potential for therapeutic development.
Pharmacol Res. 110:52–64. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kamal FA, Travers JG, Schafer AE, Ma Q,
Devarajan P and Blaxall BC: G protein-coupled receptor-G-protein
βγ-subunit signaling mediates renal dysfunction and fibrosis in
heart failure. J Am Soc Nephrol. 28:197–208. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Schumacher SM, Gao E, Zhu W, Chen X,
Chuprun JK, Feldman AM, Tesmer JJ and Koch WJ: Paroxetine-mediated
GRK2 inhibition reverses cardiac dysfunction and remodeling after
myocardial infarction. Sci Transl Med. 7(277ra31)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Murga C, Arcones AC, Cruces-Sande M,
Briones AM, Salaices M and Mayor Jr F: G protein-coupled receptor
kinase 2 (GRK2) as a potential therapeutic target in cardiovascular
and metabolic diseases. Front Pharmacol. 10(112)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Casey LM, Pistner AR, Belmonte SL,
Migdalovich D, Stolpnik O, Nwakanma FE, Vorobiof G, Dunaevsky O,
Matavel A, Lopes CMB, et al: Small molecule disruption of G
signaling inhibits the progression of heart failure. Circ Res.
107:532–539. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Daaka Y, Luttrell LM and Lefkowitz RJ:
Switching of the coupling of the beta2-adrenergic receptor to
different G proteins by protein kinase A. Nature. 390:88–91.
1997.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Senarath K, Kankanamge D, Samaradivakara
S, Ratnayake K, Tennakoon M and Karunarathne A: Regulation of G
protein βγ signaling. Int Rev Cell Mol Biol. 339:133–191.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tang X, Sun Z, Runne C, Madsen J, Domann
F, Henry M, Lin F and Chen S: A critical role of Gbetagamma in
tumorigenesis and metastasis of breast cancer. J Biol Chem.
286:13244–13254. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xu S, Zhang Z, Ogawa O, Yoshikawa T,
Sakamoto H, Shibasaki N, Goto T, Wang L and Terada N: An EP4
antagonist ONO-AE3-208 suppresses cell invasion, migration, and
metastasis of prostate cancer. Cell Biochem Biophys. 70:521–527.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu Y, Pan YF, Xue YQ, Fang LK, Guo XH,
Guo X, Liu M, Mo BY, Yang MR, Liu F, et al: uPAR promotes
tumor-like biologic behaviors of fibroblast-like synoviocytes
through PI3K/Akt signaling pathway in patients with rheumatoid
arthritis. Cell Mol Immunol. 15:171–181. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nygaard G and Firestein GS: Restoring
synovial homeostasis in rheumatoid arthritis by targeting
fibroblast-like synoviocytes. Nat Rev Rheumatol. 16:316–333.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rajagopal S and Shenoy SK: GPCR
desensitization: Acute and prolonged phases. Cell Signal. 41:9–16.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Smith JS and Rajagopal S: The β-Arrestins:
Multifunctional regulators of G protein-coupled receptors. J Biol
Chem. 291:8969–8977. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kamal FA, Smrcka AV and Blaxall BC: Taking
the heart failure battle inside the cell: Small molecule targeting
of Gβγ subunits. J Mol Cell Cardiol. 51:462–467. 2011.PubMed/NCBI View Article : Google Scholar
|
